New Automated Periostin Immunoassay Developed

The assay has been developed for use with the ARCHITECT Immunoassay i System.

Samples from subjects with idiopathic pulmonary fibrosis, subjects with asthma used in periostin concentration assessments, and normal samples from healthy volunteers were obtained. The test is a monoclonal antibody (mAb) sandwich two-step immunoassay for the quantitative determination of periostin in human serum using chemiluminescent magnetic immunoassay technology. Periostin, the analyte, is captured by microparticles coated with an anti-periostin mAb and subsequently detected with a second anti-periostin mAb conjugated with Acridinium.

The team reported that the percentage of coefficient of variation (CVs) for five-day total precision, assessed using two instruments was less than 6% across two controls and one serum-based panel. Limit of quantitation was 4 ng/mL, using dilution adjusted concentration, suiting the needs for the application. Dilution analysis yielded linear results and no endogenous sample or drug interferences were observed. All known periostin isoforms expressed in the mature human lung were detected by the assay.

The authors concluded that their analysis of periostin concentration in serum samples appeared to show slightly elevated mean periostin concentrations in samples from subjects with uncontrolled asthma compared with apparently healthy volunteers. This is consistent with reports of elevated serum periostin concentration in subjects with asthma, particularly those with Th2-driven asthma or eosinophilic inflammation. The study was published in the January 2017 issue of the journal Clinica Chimica Acta.

Related Links:
Abbott Laboratories